How should we interpret conclusions of TKI-stopping studies.

"Competing interests RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; A speaker for Janssen Pharma and Hengrui Pharma; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd."

"Profs. Jane Apperley (Imperial College London), Giuseppe Saglio (Univ. Torino), Charles Schiffer (Karmanos Cancer Center) and Andreas Hochhaus (Jena Univ.) kindly reviewed the typescript and provided valuable comments. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Center and the Ministry of Science and Technology of China (84000-51200002). JC acknowledges support from the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-001 and 2022-I2M-2-003)."